149 related articles for article (PubMed ID: 8142357)
1. Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation.
Nikiforovich GV; Kao JL; Plucinska K; Zhang WJ; Marshall GR
Biochemistry; 1994 Mar; 33(12):3591-8. PubMed ID: 8142357
[TBL] [Abstract][Full Text] [Related]
2. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
Zhang WJ; Nikiforovich GV; Pérodin J; Richard DE; Escher E; Marshall GR
J Med Chem; 1996 Jul; 39(14):2738-44. PubMed ID: 8709104
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem.
Nikiforovich GV; Marshall GR
Biochem Biophys Res Commun; 1993 Aug; 195(1):222-8. PubMed ID: 8363604
[TBL] [Abstract][Full Text] [Related]
4. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.
Matsoukas JM; Polevaya L; Ancans J; Mavromoustakos T; Kolocouris A; Roumelioti P; Vlahakos DV; Yamdagni R; Wu Q; Moore GJ
Bioorg Med Chem; 2000 Jan; 8(1):1-10. PubMed ID: 10968258
[TBL] [Abstract][Full Text] [Related]
5. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs.
Joseph MP; Maigret B; Scheraga HA
Int J Pept Protein Res; 1995 Dec; 46(6):514-26. PubMed ID: 8748712
[TBL] [Abstract][Full Text] [Related]
6. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
Plucinska K; Kataoka T; Yodo M; Cody WL; He JX; Humblet C; Lu GH; Lunney E; Major TC; Panek RL
J Med Chem; 1993 Jun; 36(13):1902-13. PubMed ID: 8515427
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments.
Wilkes BC; Masaro L; Schiller PW; Carpenter KA
J Med Chem; 2002 Sep; 45(20):4410-8. PubMed ID: 12238921
[TBL] [Abstract][Full Text] [Related]
8. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
[TBL] [Abstract][Full Text] [Related]
9. Solution conformations of the peptide backbone for DPDPE and its beta-MePhe4-substituted analogs.
Nikiforovich GV; Prakash OM; Gehrig CA; Hruby VJ
Int J Pept Protein Res; 1993 Apr; 41(4):347-61. PubMed ID: 8496017
[TBL] [Abstract][Full Text] [Related]
10. The utility of side-chain cyclization in determining the receptor-bound conformation of peptides: cyclic tripeptides and angiotensin II.
Kataoka T; Beusen DD; Clark JD; Yodo M; Marshall GR
Biopolymers; 1992 Nov; 32(11):1519-33. PubMed ID: 1333831
[TBL] [Abstract][Full Text] [Related]
11. Solution conformations of two flexible cyclic pentapeptides: cyclo(Gly-Pro-D-Phe-Gly-Ala) and cyclo(Gly-Pro-D-Phe-Gly-Val).
Stroup AN; Rockwell AL; Gierasch LM
Biopolymers; 1992 Dec; 32(12):1713-25. PubMed ID: 1472654
[TBL] [Abstract][Full Text] [Related]
12. Combined use of molecular dynamics simulations and NMR to explore peptide bond isomerization and multiple intramolecular hydrogen-bonding possibilities in a cyclic pentapeptide, cyclo(Gly-Pro-D-Phe-Gly-Val).
Liu ZP; Gierasch LM
Biopolymers; 1992 Dec; 32(12):1727-39. PubMed ID: 1472655
[TBL] [Abstract][Full Text] [Related]
13. Structural features of angiotensin II which are important for biologic activity.
Peach MJ
Kidney Int Suppl; 1979 Mar; (9):S3-6. PubMed ID: 289861
[TBL] [Abstract][Full Text] [Related]
14. The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment.
Carpenter KA; Wilkes BC; Schiller PW
Eur J Biochem; 1998 Jan; 251(1-2):448-53. PubMed ID: 9492317
[TBL] [Abstract][Full Text] [Related]
15. Conformational analysis of beta-methyl-para-nitrophenylalanine stereoisomers of cyclo[D-Pen2, D-Pen5]enkephalin by NMR spectroscopy and conformational energy calculations.
Shenderovich MD; Kövér KE; Nikiforovich GV; Jiao D; Hruby VJ
Biopolymers; 1996 Feb; 38(2):141-56. PubMed ID: 8589249
[TBL] [Abstract][Full Text] [Related]
16. On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?
Tzakos AG; Gerothanassis IP; Troganis AN
Curr Top Med Chem; 2004; 4(4):431-44. PubMed ID: 14965310
[TBL] [Abstract][Full Text] [Related]
17. An investigation of angiotensin II agonist and antagonist analogues with 5,5-dimethylthiazolidine-4-carboxylic acid and other constrained amino acids.
Samanen J; Cash T; Narindray D; Brandeis E; Adams W; Weideman H; Yellin T; Regoli D
J Med Chem; 1991 Oct; 34(10):3036-43. PubMed ID: 1920354
[TBL] [Abstract][Full Text] [Related]
18. Solvent effects on the conformation of cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu-). An NMR spectroscopy and molecular modeling study.
Gonnella NC; Zhang X; Jin Y; Prakash O; Paris CG; Kolossváry I; Guida WC; Bohacek RS; Vlattas I; Sytwu T
Int J Pept Protein Res; 1994 May; 43(5):454-62. PubMed ID: 8070969
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5.
Schmidt B; Lindman S; Tong W; Lindeberg G; Gogoll A; Lai Z; Thörnwall M; Synnergren B; Nilsson A; Welch CJ; Sohtell M; Westerlund C; Nyberg F; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):903-19. PubMed ID: 9083479
[TBL] [Abstract][Full Text] [Related]
20. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
